

pending claims ("Appendix A"), a Declaration Under 37 C.F.R. §1.132 ("Appendix B"), and a Table ("Appendix C"). Please amend the above-identified application as follows:

**In the claims:**

Please cancel claims 113-120, 124-131, 134, 135, 150, 196-201, 204-211, and 213-219, without prejudice, and amend claims 123, 132, 133, 149, 220, 221, 222, 223, and 224 as follows:

**123. (Amended)** An isolated polypeptide of any one of claims 202-203 which is a recombinant polypeptide.

**132. (Amended)** A fusion protein comprising a polypeptide of any one of claims 202-203 and an additional amino acid sequence.

**133. (Amended)** A fusion protein of claim 132, wherein the additional amino acid sequence comprises an *H. pylori* polypeptide.

**149. (Amended)** A composition comprising a polypeptide of any one of claims 202-203 and a pharmaceutically acceptable carrier.

**220. (Amended)** An isolated polypeptide of any one of claims 202-203 comprising at least about 12 consecutive amino acid residues of SEQ ID NO:764.

**221. (Amended)** An isolated polypeptide of any one of claims 202-203 comprising at least about 16 consecutive amino acid residues of SEQ ID NO:764.

**222. (Amended)** An isolated polypeptide of any one of claims 202-203 comprising at least about 20 consecutive amino acid residues of SEQ ID NO: 764.